JP2011528345A - 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用 - Google Patents

抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用 Download PDF

Info

Publication number
JP2011528345A
JP2011528345A JP2011518028A JP2011518028A JP2011528345A JP 2011528345 A JP2011528345 A JP 2011528345A JP 2011518028 A JP2011518028 A JP 2011518028A JP 2011518028 A JP2011518028 A JP 2011518028A JP 2011528345 A JP2011528345 A JP 2011528345A
Authority
JP
Japan
Prior art keywords
treatment
idrabiotaparinux
bleeding
months
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518028A
Other languages
English (en)
Japanese (ja)
Inventor
カリウ，ロジエ
チユー，ポール
デストール，ジヤン−ミシエル
ピヨン，ジエラール
シルベストル，ルイーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08290704A external-priority patent/EP2145624A1/en
Priority claimed from EP09290216A external-priority patent/EP2233143A1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011528345A publication Critical patent/JP2011528345A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011518028A 2008-07-18 2009-07-17 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用 Pending JP2011528345A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08290704A EP2145624A1 (en) 2008-07-18 2008-07-18 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP08290704.9 2008-07-18
EP09290216.2 2009-03-24
EP09290216A EP2233143A1 (en) 2009-03-24 2009-03-24 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
PCT/IB2009/006621 WO2010007530A1 (en) 2008-07-18 2009-07-17 Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment

Publications (1)

Publication Number Publication Date
JP2011528345A true JP2011528345A (ja) 2011-11-17

Family

ID=41203891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518028A Pending JP2011528345A (ja) 2008-07-18 2009-07-17 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用

Country Status (15)

Country Link
US (1) US20110245200A1 (zh)
EP (1) EP2315593A1 (zh)
JP (1) JP2011528345A (zh)
KR (1) KR20110044747A (zh)
CN (1) CN102149389A (zh)
AR (1) AR072520A1 (zh)
AU (1) AU2009272373A1 (zh)
BR (1) BRPI0915947A2 (zh)
CA (1) CA2730975A1 (zh)
IL (1) IL210692A0 (zh)
MX (1) MX2011000673A (zh)
RU (1) RU2011106037A (zh)
TW (1) TW201006479A (zh)
UY (1) UY31995A (zh)
WO (1) WO2010007530A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2839139A1 (en) * 2011-06-17 2012-12-20 Carbomimetics Synthetic pentasaccharides having short half-life and high activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509902A (ja) * 2000-09-22 2004-04-02 サノフィ−サンテラボ ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
JP5060486B2 (ja) * 2005-10-10 2012-10-31 エム・エス・ディー・オス・ベー・フェー ビオチン標識を含む抗凝固抗血栓二重阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509902A (ja) * 2000-09-22 2004-04-02 サノフィ−サンテラボ ビオチンまたはビオチン誘導体との少なくとも一つの共有結合を含み抗血栓活性を有するポリサッカライド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013043219; Ｐｒａｎｄｏｎｉ　ｅｔ　ａｌ．: ''Ｉｄｒａｐａｒｉｎｕｘ：　ｒｅｖｉｅｗ　ｏｆ　ｉｔｓ　ｃｌｉｎｉｃａｌ　ｅｆｆｉｃａｃｙ　ａｎｄ　ｓａｆｅｔｙ　ｆｏｒ　ｐｒｅｖｅｎｔｉｏｎ　ａｎｄ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｔｈｒｏｍｂｏｅｍｂｏ' Ｅｘｐｅｒｔ　Ｏｐｉｎｉｏｎ　ｏｎ　Ｉｎｖｅｓｔｉｇａｔｉｏｎａｌ　Ｄｒｕｇｓ Ｖｏｌ．１７，　Ｎｏ．５　（Ｍａｙ　２００８）, ｐｐ．７７３-７７７ *
JPN6013043220; Ｈｉｒｓｈ　ｅｔ　ａｌ．: ''Ｂｅｙｏｎｄ　Ｕｎｆｒａｃｔｉｏｎａｔｅｄ　Ｈｅｐａｒｉｎ　ａｎｄ　Ｗａｒｆａｒｉｎ：　Ｃｕｒｒｅｎｔ　ａｎｄ　Ｆｕｔｕｒｅ　Ａｄｖａｎｃｅｓ'' Ｃｉｒｃｕｌａｔｉｏｎ ２００７；１１６, ｐｐ．５５２-５６０ *

Also Published As

Publication number Publication date
BRPI0915947A2 (pt) 2019-04-09
MX2011000673A (es) 2011-04-04
US20110245200A1 (en) 2011-10-06
CN102149389A (zh) 2011-08-10
IL210692A0 (en) 2011-03-31
TW201006479A (en) 2010-02-16
CA2730975A1 (en) 2010-01-21
EP2315593A1 (en) 2011-05-04
WO2010007530A1 (en) 2010-01-21
UY31995A (es) 2010-02-26
AR072520A1 (es) 2010-09-01
RU2011106037A (ru) 2012-08-27
KR20110044747A (ko) 2011-04-29
AU2009272373A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
JP6922092B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
Goto et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice
AU2002305952A1 (en) Pharmaceutical combinations
WO2002096428A1 (en) Pharmaceutical combinations
JP2011529958A (ja) 脳卒中または一過性脳虚血発作を予防するための薬物を調製するためのドロネダロンの使用
CZ20013757A3 (cs) Farmaceutická kompozice obsahující inhibitor trombinu o nízké molekulové hmotnosti a jeho prekuzor
JP2012522805A (ja) ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
JPWO2013089164A1 (ja) 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
JP2011528345A (ja) 抗血栓治療中の出血率を低下させるためのイドラビオタパリナックスの使用
CN112672743A (zh) 肝病瘙痒症状的治疗
KR20240060820A (ko) 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안
Karthikeyan et al. New oral anticoagulants: not quite there yet
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
AU2001225625A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
EP1333855A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
EP2145624A1 (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
EP2233143A1 (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
Salemis Rivaroxaban-induced chest wall spontaneous expanding hematoma
後藤昌希 et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice
Simbirtseva P1655 Effect of antihypertensive treatment with indapamide on bone metabolism in patients with arterial hypertension and osteoarthritis
JP2014504625A (ja) 肺塞栓症の治療および静脈血栓塞栓イベントの二次予防のためのイドラバイオタパリヌクス
Zeymer Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome
WO2012134828A1 (en) Methods for treating heartburn and/or preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
TW201309304A (zh) 用於肺部栓塞症之治療及用於靜脈血栓性栓塞症之二級預防之生物素化艾屈肝素（ｉｄｒａｂｉｏｔａｐａｒｉｎｕｘ）

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140826